Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.
Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
Br J Haematol. 2022 Mar;196(5):1219-1224. doi: 10.1111/bjh.17989. Epub 2021 Dec 5.
Studies on the conditional life expectancy of patients with chronic myeloid leukaemia (CML) are lacking. Using data from the Netherlands Cancer Registry, we examined the life expectancy of patients with CML in the Netherlands diagnosed during 1989-2018. As of the early 2010s, the life expectancy of patients with CML who survived several years after diagnosis came narrowly close to the general population's life expectancy, regardless of age. This finding can essentially be ascribed to the introduction and broader application of tyrosine kinase inhibitors (TKIs) and provide optimism to patients with CML who can look forward to a near-normal life expectancy in a modern TKI era.
关于慢性髓性白血病（CML）患者条件预期寿命的研究尚不多见。利用荷兰癌症登记处的数据，我们调查了在 1989 年至 2018 年期间被诊断患有 CML 的荷兰患者的预期寿命。自 21 世纪 10 年代初以来，无论年龄大小，在诊断后存活数年的 CML 患者的预期寿命已接近接近普通人群的预期寿命。这一发现主要归因于酪氨酸激酶抑制剂（TKI）的引入和更广泛的应用，并为 CML 患者带来了乐观的前景，使他们有望在现代 TKI 时代拥有接近正常的预期寿命。
